Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2010 Jul;51(6):527-39.
doi: 10.1002/em.20557.

Targeting and processing of site-specific DNA interstrand crosslinks

Karen M Vasquez  1
Affiliations
Review

Targeting and processing of site-specific DNA interstrand crosslinks

Karen M Vasquez. Environ Mol Mutagen. 2010 Jul.

Abstract

DNA interstrand crosslinks (ICLs) are among the most cytotoxic types of DNA damage, and thus ICL-inducing agents such as cyclophosphamide, melphalan, cisplatin, psoralen, and mitomycin C have been used clinically as anticancer drugs for decades. ICLs can also be formed endogenously as a consequence of cellular metabolic processes. ICL-inducing agents continue to be among the most effective chemotherapeutic treatments for many cancers; however, treatment with these agents can lead to secondary malignancies, in part due to mutagenic processing of the DNA lesions. The mechanisms of ICL repair have been characterized more thoroughly in bacteria and yeast than in mammalian cells. Thus, a better understanding of the molecular mechanisms of ICL processing offers the potential to improve the efficacy of these drugs in cancer therapy. In mammalian cells, it is thought that ICLs are repaired by the coordination of proteins from several pathways, including nucleotide excision repair (NER), base excision repair (BER), mismatch repair (MMR), homologous recombination (HR), translesion synthesis (TLS), and proteins involved in Fanconi anemia (FA). In this review, we focus on the potential functions of NER, MMR, and HR proteins in the repair of and response to ICLs in human cells and in mice. We will also discuss a unique approach, using psoralen covalently linked to triplex-forming oligonucleotides to direct ICLs to specific sites in the mammalian genome.

PubMed Disclaimer

Figures

Figure 1
Figure 1. Model of ICL repair in mammalian cells
The schematic depicts two modes of ICL processing in mammalian cells. On the left (“G0/G1”) is a potential pathway of ICL repair in nonreplicating cells; and on the right (“S”) is a potential pathway of ICL repair in replicating cells
Figure 2
Figure 2. Target duplex and psoralen-modified TFO
(A) Space-filling model of a psoralen-modified TFO bound to its target duplex. The psoralen moiety is shown in yellow and the TFO is shown in red bound to the purine-rich strand of the target duplex (blue) in the major groove. The pyrimidine-rich strand is shown in green. (B) The TFO binding site is shown in red, the psoralen crosslinking site is shown in yellow, and the pyrimidine-rich (py) and purine-rich (pu) strands are depicted in green and blue, respectively. The sequence of the TFO binding site is shown in bold capital letters, the psoralen crosslinking site is underlined (Christensen et al. 2008)
Figure 3
Figure 3. Potential interactions between NER and MMR proteins in processing ICLs
Two general models by which MutSβ (MSH2-3) may participate in ICL processing. In (i), participates in damage recognition of an ICL and acts as an accessory factor to NER proteins for ICL unhooking. This is experimentally supported by the known binding of MutSβ to an ICL and the enhancement of incision and repair synthesis at an ICL. In (ii), MutSβ acts to help recruit and anchor ERCC1-XPF to an ICL. When the ICL is present at a structure such as a blocked replication fork, ERCC1-XPF can cleave near the crosslink. Alternatively, rather than unhooking, a cleavage reaction by ERCC1-XPF could occur during recombinational processing of a broken replication fork. A catalytic role for MLH1-PMS2 is also possible, for example utilizing its nuclease activity in an end-processing reaction
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Aboussekhra A, Biggerstaff M, Shivji MK, Vilpo JA, Moncollin V, Podust VN, Protic M, Hubscher U, Egly JM, Wood RD. Mammalian DNA nucleotide excision repair reconstituted with purified protein components. Cell. 1995;80(6):859–68. - PubMed
    1. Adamson AW, Beardsley DI, Kim WJ, Gao Y, Baskaran R, Brown KD. Methylator-induced, mismatch repair-dependent G2 arrest is activated through Chk1 and Chk2. Mol Biol Cell. 2005;16(3):1513–26. - PMC - PubMed
    1. Aebi S, Fink D, Gordon R, Kim HK, Zheng H, Fink JL, Howell SB. Resistance to cytotoxic drugs in DNA mismatch repair-deficient cells. Clin Cancer Res. 1997;3(10):1763–7. - PubMed
    1. Akkari YM, Bateman RL, Reifsteck CA, Olson SB, Grompe M. DNA replication is required To elicit cellular responses to psoralen- induced DNA interstrand cross-links. Mol Cell Biol. 2000;20(21):8283–9. - PMC - PubMed
    1. Aquilina G, Crescenzi M, Bignami M. Mismatch repair, G(2)/M cell cycle arrest and lethality after DNA damage. Carcinogenesis. 1999;20(12):2317–26. - PubMed

Substances